Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 5/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908432 | 1.00 | SCN9A (0.42) | SCN9AFPR2CXCR3MKNK1MKNK2 | |
| SCHEMBL908476 | 0.90 | SMO (0.41) | SCN9AFPR2CXCR3 | |
| SCHEMBL908474 | 0.90 | SMO (0.41) | SCN9AFPR2CXCR3 | |
| SCHEMBL907847 | 0.89 | KHK (0.41) | SCN9ACXCR3P2RY12AOC3SYK | |
| SCHEMBL907972 | 0.89 | KHK (0.41) | SCN9ACXCR3P2RY12AOC3SYK | |
| SCHEMBL907878 | 0.83 | CXCR3 (0.40) | CXCR3MKNK1MKNK2AOC3SYK | |
| SCHEMBL907877 | 0.83 | CXCR3 (0.40) | CXCR3MKNK1MKNK2AOC3SYK | |
| SCHEMBL908597 | 0.82 | FPR2 (0.41) | SCN9AFPR2CXCR3 | |
| SCHEMBL908596 | 0.82 | FPR2 (0.41) | SCN9AFPR2CXCR3 | |
| SCHEMBL908128 | 0.82 | CXCR3 (0.43) | SCN9AFPR2CXCR3P2RY12SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | claimed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| EP-1786800-A4 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORP (US) | 2009-05-06 | — | — | EP | claimed |
| EP-1786800-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | claimed |
| WO-2006026135-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-03-09 | — | — | WO | claimed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | SCN9A 3115/4885FPR2 222/4885CXCR3 1012/4885 |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | SCN9A 3068/4885FPR2 232/4885CXCR3 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.